Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Other Accumulated Expenses (2016 - 2023)

Editas Medicine (EDIT) has disclosed Other Accumulated Expenses for 9 consecutive years, with $78000.0 as the latest value for Q2 2023.

  • On a quarterly basis, Other Accumulated Expenses fell 97.18% to $78000.0 in Q2 2023 year-over-year; TTM through Jun 2023 was $78000.0, a 97.18% decrease, with the full-year FY2022 number at $1.6 million, up 16.12% from a year prior.
  • Other Accumulated Expenses was $78000.0 for Q2 2023 at Editas Medicine, down from $109000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $2.8 million in Q2 2022 to a low of $78000.0 in Q2 2023.
  • A 5-year average of $769722.2 and a median of $570000.0 in 2019 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: surged 202.19% in 2022, then tumbled 97.18% in 2023.
  • Editas Medicine's Other Accumulated Expenses stood at $599000.0 in 2019, then skyrocketed by 88.65% to $1.1 million in 2020, then increased by 24.6% to $1.4 million in 2021, then increased by 16.12% to $1.6 million in 2022, then tumbled by 95.23% to $78000.0 in 2023.
  • Per Business Quant, the three most recent readings for EDIT's Other Accumulated Expenses are $78000.0 (Q2 2023), $109000.0 (Q1 2023), and $1.6 million (Q4 2022).